Overview
Location
United States, Massachusetts, Newton
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 3, 2011 | Neoprobe hires ex-Alseres Pharma executive as chief business officer | Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has hired a former Alseres Pharmaceuticals executive as its new chief business officer. Thomas Tulip will help the Dublin, Ohio-based company seek out business opportunities for two radio... |
| Mar 31, 2011 | New Neoprobe CEO: Lymphoseek NDA pushed back to third quarter | The newly installed CEO of cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) said the company is again delaying its FDA application to commercialize its radiopharmaceutical Lymphoseek. As recently as earlier this month, the company said it ... |
| Nov 16, 2010 | Neoprobe taps pharma vet Pykett as development chief | Neoprobe Corp. (OTC:NEOP) hired a biotechnology and pharmaceuticals industry veteran as its chief development officer. Mark Pykett, 46, is stepping into the role, which calls for him to assist the company with its product and business devel... |
| Neoprobe hires ex-Alseres Pharma executive as chief business officer | Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has hired a former Alseres Pharmaceuticals executive as its new chief business officer. Thomas Tulip will help the Dublin, Ohio-based company seek out business opportunities for two radio... | |
| Navidea signs option to license Parkinson’s imaging agent from Alseres | Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has signed a deal that gives it the option to license a Parkinson’s disease imaging agent from Alseres Pharmaceuticals. Under the terms of the deal, Navidea (formerl... | |
| New Neoprobe CEO: Lymphoseek NDA pushed back to third quarter | The newly installed CEO of cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) said the company is again delaying its FDA application to commercialize its radiopharmaceutical Lymphoseek. As recently as earlier this month, the company said it ... |